Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus

Background and Objectives: Belimumab (BEL) is a monoclonal antibody approved for the treatment of active systemic lupus erythematosus (SLE) but not for lupus nephritis (LN) and neuropsychiatric systemic lupus erythematosus (NPSLE). We aimed to assess BEL's effects on these severe, potentially l...

Descripción completa

Detalles Bibliográficos
Autores principales: Plüß, Marlene, Tampe, Björn, Niebusch, Noah, Zeisberg, Michael, Müller, Gerhard A., Korsten, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267006/
https://www.ncbi.nlm.nih.gov/pubmed/32537456
http://dx.doi.org/10.3389/fmed.2020.00222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267006/
https://www.ncbi.nlm.nih.gov/pubmed/32537456
http://dx.doi.org/10.3389/fmed.2020.00222

Ejemplares similares